Celigo Advances studies in T Cell Therapy as a pediatric CHOP patient defeats her recurrent leukemia with immunotherapy

photo

Emily Whitehead, cancer survivor, holding Nexcelom cell counting sheep.

Thanks to the lifesaving T cell therapy clinical trial at Children’s Hospital of Philadelphia, Emily Whitehead is now two years cancer free. Diagnosed with acute lymphoblastic leukemia (ALL) right after her 5th birthday, doctors discovered that Emily’s leukemia was particularly resistant to chemotherapy, as are roughly 15% of the total number of ALL cases. After two recurrences of the disease, Emily’s parents enrolled her in a clinical trial for CTL019, an experimental therapeutic using a patient’s own reprogrammed T cells to eliminate the cancer cells. Now 9 years old, happy and healthy, Emily can finally lead a normal life. All evidence of the disease is gone, and Emily’s cancer-fighting T cells remain.

The Celigo is part of the growing tool box of technologies that are advancing T cell therapy research for patients with ALL and other cancers such as non-Hodgkin lymphoma, breast cancer, and other advanced stage cancers. To read more about Emily’s incredible story visit her website, Emily Whitehead :: My Journey Fighting Leukemia

To learn more about the Celigo Image Cytometer, you can reach out at info@nexcelom.com or call to speak with one of our specialists at 978-327-5340

Leave A Comment